These pathological findings parallel the MS real clinical life where often GAD+ lesions at MRI, thought a surrogate marker of BBB alteration13, were also detected during clinical stability stages independently of occurrence of new clinical relapses14,15. This evidence concerns the gene GAD1 and myeloid sarcoma.